Siemens Healthineers stock steadies as 2027 outlook stays in focus

Siemens Healthineers stock traded at 43.50 euros on Lang & Schwarz at 18:05 CET on Wednesday, November 11, 2026, 0.05 percent below the Xetra close of Wednesday at 43.52 euros. The latest market level leaves investors focused on whether the company can convert a strong fourth quarter into steadier earnings growth.

Strong Finish, Softer Guidance

Siemens Healthineers said in its fiscal 2026 results release, published on November 5, that comparable revenue rose 4.0 percent for the year. Adjusted EBIT margin reached 16.2 percent, adjusted basic earnings per share came to 2.42 euros, and the proposed dividend remained 1.00 euro per share.

The fourth quarter delivered comparable revenue growth of 5.9 percent. Imaging led with 10.0 percent growth, while Precision Therapy advanced 4.8 percent. Diagnostics moved in the opposite direction, with comparable revenue declining 4.2 percent and its adjusted EBIT margin at 5.4 percent.

2027 Earnings Face Several Pressures

Management expects comparable revenue growth of 4.0 to 5.0 percent in fiscal 2027 and adjusted basic earnings per share of 2.20 to 2.40 euros. The range is below the 2026 reported level, putting execution, cost control and portfolio changes at the center of the investor debate.

The company is also positioning its Diagnostics business for a carve-out while sharpening its focus on the remaining healthcare technology portfolio. The next scheduled company milestone is publication of the fiscal 2026 annual report on November 25.

Across the DAX, investors are weighing resilient industrial demand against more selective expectations for earnings growth.

More news and analyses on Siemens Healthineers stock.